Principal Scientist, Drug Safety and Metabolism at AstraZeneca
Richard Goodwin has been with AstraZeneca since 2011 and leads the mass spectrometry imaging team. The group uses MS imaging to investigate the efficacy and safety of new medicines and supports projects from early discovery through to the clinic. Prior to starting with AstraZeneca in the UK, Richard was an AstraZeneca funded postdoctoral researcher at Uppsala, Sweden. He received his PhD from University of Edinburgh in 2006 followed by a postdoctoral position at University of Glasgow. He collaborates with a wide range of academic researchers developing and employing molecular imaging technologies.